^
Association details:
Evidence:
Evidence Level:
Sensitive: D – Preclinical
Source:
Title:

P6-10-10 Genetic alterations in breast cancer associated with MDM2 dependency and sensitivity to the MDM2 inhibitor milademetan

Published date:
11/22/2022
Excerpt:
Preclinical data show that the MDM2 inhibitor milademetan has antitumor activity in GATA3-mutant and MDM2-amplified HR+ breast cancers, and support the clinical evaluation of milademetan in these tumors.